Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2026)

Camp4 Therapeutics (CAMP) has 3 years of Current Deferred Revenue data on file, last reported at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (changed N/A YoY), and the FY2025 full-year result was $9.4 million, up 2338.18% from the prior year.
• Current Deferred Revenue advanced to $11.1 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.1 million in Q1 2026 to a low of $385000.0 in Q4 2024.
• A 3-year average of $5.5 million and a median of $5.2 million in 2024 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 2338.18% in 2025, while the deepest fall reached 2338.18% in 2025.
• Tracing CAMP's Current Deferred Revenue over 3 years: stood at $385000.0 in 2024, then jumped by 2338.18% to $9.4 million in 2025, then gained by 17.98% to $11.1 million in 2026.
• Business Quant data shows CAMP's Current Deferred Revenue at $11.1 million in Q1 2026, $9.4 million in Q4 2025, and $385000.0 in Q4 2024.